Comparison of Adjunctive Naoxintong versus Clopidogrel in Volunteers with the CYP2C19^*2 Gene Mutation Accompanied with Qi Deficiency and Blood Stasis Constitution

Table 3

Comparison of platelet count, platelet activation, and inflammation at baseline and after therapy.

	Baseline	7 d after single clopidogrel administration	𝑃 value	5 d after single BNJ- administration	𝑃 value	7 d after BNJ- combined clopidogrel	𝑃 value
Platelet count (× 10^9/L)
CYP2C19*1/*1 (𝑛=6)	236.0±37.9	228.7±42.60	.172	239.7±35.5	.315	224.7±30.0	.093
CYP2C19*1/*2 (𝑛=6)	257.7±32.85	253.5±33.8	.627	251.3±21.2	.474	254.2±30.0	.489
CYP2C19*2/*2 (𝑛=6)	263.8±42.2	266.7±26.6	.890	234.8±52.5	.037	245.0±29.6	.085
CD62P platelet positive (%)
CYP2C19*1/*1 (𝑛=6)	38.6±2.7	27.0±2.6	.001	26.9±2.1	.001	26.0±2.8	.001
CYP2C19*1/*2 (𝑛=6)	38.8±1.9	32.6±1.7	<.001	27.0±2.2	<.001	26.2±2.6	<.001
CYP2C19*2/*2 (𝑛=6)	38.4±1.9	36.6±2.0	.001	26.7±1.9	<.001	22.2±1.1	<.001
PAC-1 platelet positive (%)
CYP2C19*1/*1 (𝑛=6)	40.6±4.9	28.1±2.6	<.001	25.9±4.6	<.001	25.3±4.5	<.001
CYP2C19*1/*2 (𝑛=6)	40.0±2.3	35.9±1.9	<.001	29.9±2.2	<.001	23.4±0.7	<.001
CYP2C19*2/*2 (𝑛=6)	38.1±3.2	34.9±2.0	<.001	27.3±3.4	<.001	20.4±1.2	<.001
Inflammatory marker sCD40L (ng/mL)
CYP2C19*1/*1 (𝑛=6)	3.3±0.9	1.3±0.3	.001	1.9±0.7	.001	1.2±0.3	.001
CYP2C19*1/*2 (𝑛=6)	3.2±0.7	2.2±0.4	.002	2.2±0.4	.002	1.3±0.3	.001
CYP2C19*2/*2 (𝑛=6)	3.1±0.2	2.6±0.5	.007	2.4±0.4	.007	1.2±0.3	<.001

Note: values are presented as mean ± SD. The 𝑃 values are for comparison to baseline. CD62p: platelet activation of the membrane marker P-selectin; PAC-1: antibody against activated glycoprotein IIb/IIIa; sCD40L: soluble CD40L.